Nephros (NEPH) vs TELA Bio (TELA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TELA Bio (TELA) has outperformed Nephros (NEPH) over the past year, losing 41.2% versus a loss of 46.4%. Over five years, NEPH leads with a -63.6% price change compared with -94.4% for TELA. TELA Bio is the larger company by market cap ($31.1 million vs $28.4 million), about 1.1 times the size, while Nephros is growing revenue faster (+32.7% vs +15.8%).
Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -48.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEPH | TELA |
|---|---|---|
| Share price | $2.61 | $0.6885 |
| Market cap | $28.37M | $31.11M |
| 1-day change | -8.10% | -5.27% |
| YTD return | -46.52% | -41.65% |
| 1-year return | -46.41% | -41.15% |
| 5-year return | -63.60% | -94.37% |
| P/E ratio (TTM) | 15.35 | — |
| Forward P/E | 11.86 | — |
| EPS (TTM) | $0.17 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $18.79M | $80.28M |
| Revenue growth (YoY) | +32.67% | +15.84% |
| Net income (latest FY) | $1.19M | $-38.83M |
| Gross margin | 61.87% | 67.69% |
| Operating margin | 6.10% | -42.05% |
| Net margin | 6.35% | -48.37% |
| 52-week high | $6.42 | $1.50 |
| 52-week low | $2.61 | $0.501 |
| Distance from 52-week high | -59.35% | -54.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +139.46% | +202.11% |
| Average volume | 48.33K | 217.44K |
| Shares outstanding | 10.87M | 45.19M |
| Employees | 36 | 218 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -48.4 cents for TELA Bio.
- Nephros grew revenue faster in its latest fiscal year (+32.67% vs +15.84%).
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
About TELA Bio
TELA stock →TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Health Care · Medical/Dental Instruments · 218 employees
NEPH vs TELA FAQ
Which is bigger, Nephros or TELA Bio?
TELA Bio (TELA) is larger, with a market capitalization of $31.11M compared with $28.37M for Nephros (NEPH).
Which stock has performed better over the past year, NEPH or TELA?
TELA returned -41.15% over the past 12 months, compared with -46.41% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Are Nephros and TELA Bio in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.